XGN Earnings Date: Nov 10, 2026 (Estimated) — Exagen Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is XGN's next earnings date?
Exagen Inc. (XGN) is expected to report Q3 2026 earnings on Tuesday, November 10, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19 on revenue of $18.3M.
How did XGN do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Exagen Inc. posted EPS of -$0.13 versus the -$0.19 estimate, a beat of 31.6%. Revenue was $19.9M against a $17.8M estimate. The stock's 1-day post-earnings move was +37.8%.
How much does XGN stock move after earnings?
XGN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 16.0% (up or down) in the day after earnings.
About Exagen Inc.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.19 | -0.13 | +31.58% | $19.9M | ✅ Beat | +37.82% | +41.88% | +52.14% |
| 2026-05-11 | Q1 2026 | -0.25 | -0.17 | +32.00% | $17.3M | ✅ Beat | +34.92% | +23.39% | +46.10% |
| 2026-03-10 | Q4 2025 | -0.20 | -0.20 | +0.00% | $16.6M | ➖ Inline | -3.85% | -6.51% | -8.88% |
| 2025-11-04 | Q3 2025 | -0.15 | -0.19 | -26.67% | $17.2M | ❌ Miss | -8.96% | -20.03% | -38.46% |
| 2025-07-29 | Q2 2025 | -0.16 | -0.18 | -12.50% | $17.2M | ❌ Miss | +14.34% | +19.76% | +33.96% |
| 2025-05-05 | Q1 2025 | -0.21 | -0.20 | +4.76% | $15.5M | ✅ Beat | +3.82% | -5.15% | +22.76% |
| 2025-03-11 | Q4 2024 | -0.24 | -0.20 | +16.67% | $13.7M | ✅ Beat | +18.25% | +27.02% | +40.35% |
| 2024-11-12 | Q3 2024 | -0.29 | -0.28 | +3.45% | $12.5M | ✅ Beat | -6.06% | +1.01% | +72.22% |
Showing last 8 quarters.